Sarcopenia in cancer: Risking more than muscle loss
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Sarcopenia is characterised by progressive and extensive skeletal muscle degeneration and is associated with functional decline. Sarcopenia has primary and secondary aetiology, arising as a result of the ageing process or through chronic cytokine-mediated inflammation (associated with health conditions including cancer), respectively. Diagnosis of sarcopenia is dependent upon detection of reduced skeletal muscle strength, mass and performance. A combination of non-radiological and radiological methods can be used to assess each of these in turn to accurately diagnose sarcopenia. Sarcopenia is known to adversely affect outcomes of patients with various forms of cancer. Early identification of sarcopenia is imperative in improving patient care and overall prognosis. Various interventions, such as resistance exercise, nutritional support, and amino acid and vitamin supplementation have shown promise in the management of sarcopenia. However, further insight into novel interventions and indeed, assessment of the benefits of management of sarcopenia in terms of survival, are required to better support cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601 · cited 2×
“Both primary and secondary sarcopenia are of importance as they adversely affect patients’ functional status and can worsen prognosis of causative diseases [6,11].”
BackgroundAsian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070 · cited 1×
“The Asian Working Group for Sarcopenia (ASWG) defines this condition as ‘‘age-related loss of skeletal muscle mass plus loss of muscle strength and/or reduced physical performance” with population specific cut offs for measurements [8].”
BackgroundEpidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 2×
“Accordingly, in 65–70 year-olds, severe muscle loss (defined as appendicular skeletal muscle mass less than two standard deviations below young, healthy controls) has a prevalence of approximately 13–24%; whereas in over 80 year-olds, this rises to approximately 50% [2,3].”
BackgroundSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Roberts, H. C., Denison, H. J., Martin, H. J., Patel, H. P., Syddall, H., Cooper, C., & Sayer, A. A. (2011) · Age and Ageing · doi:10.1093/ageing/afr051 · Cited by 3,001
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545 · cited 1×
“Similarly, the Foundation for the National Institutes of Health defined muscle mass and muscle strength using a definite cut off [9].”
MethodSarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 1×
“In addition, lifestyle factors that are commonplace in cancer patients, such as physical inactivity and malnutrition can attenuate muscle growth and facilitate adipose tissue gain, leading to the development of sarcopenic obesity [15,23,25].”
BackgroundSpeck, R. M., Courneya, K. S., Mâsse, L. C., Duval, S., & Schmitz, K. H. (2010) · Journal of Cancer Survivorship · doi:10.1007/s11764-009-0110-5 · Cited by 1,352
SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes
Malmstrom, T. K., Miller, D. K., Simonsick, E. M., Ferrucci, L., & Morley, J. E. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12048 · Cited by 1,155 · cited 1×
“SARC-F questionnaire [42] Score of 4 Self-administered scale with highest”
Short physical performance battery and all-cause mortality: systematic review and meta-analysis
Pavasini, R., Guralnik, J., Brown, J. C., di Bari, M., Cesari, M., Landi, F., Vaes, B., Legrand, D., Verghese, J., Wang, C., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0763-7 · Cited by 911 · cited 7×
“Physical Performance tests SPPB [39] 8 Set of tests evaluating gait speed, balance and chair stand test.”
BackgroundMethodInfluentialPhysical activity for cancer survivors: meta-analysis of randomised controlled trials
Fong, D. Y. T., Ho, J. W. C., Hui, B. P. H., Lee, A. M., Macfarlane, D. J., Leung, S. S. K., Cerin, E., Chan, W. Y. Y., Leung, I. P. F., Lam, S. H. S., et al. (2012) · BMJ · doi:10.1136/bmj.e70 · Cited by 782
Pitfalls in the measurement of muscle mass: A need for a reference standard
Buckinx, F., Landi, F., Cesari, M., Fielding, R. A., Visser, M., Engelke, K., Maggi, S., Dennison, E., Al‐Daghri, N. M., Allepaerts, S., et al. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12268 · Cited by 765
Measurement of skeletal muscle radiation attenuation and basis of its biological variation
Aubrey, J., Esfandiari, N., Baracos, V. E., Buteau, F. A., Frenette, J., Putman, C. T., & Mazurak, V. C. (2014) · Acta Physiologica · doi:10.1111/apha.12224 · Cited by 720 · cited 1×
“Skeletal muscle typically occupies a CT number of approximately 50–60 HU [37,38].”
BackgroundKhalil, S., Mohktar, M., & Ibrahim, F. (2014) · Sensors · doi:10.3390/s140610895 · Cited by 712 · cited 2×
“As such, radiological methods are preferred in the assessment of muscle mass [27].”
MethodTemel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review.
the IOF-ESCEO Sarcopenia Working Group, Beaudart, C., Dawson, A., Shaw, S. C., Harvey, N. C., Kanis, J. A., Binkley, N., Reginster, J. Y., Chapurlat, R., Chan, D. C., et al. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3980-9 · Cited by 602
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574 · cited 3×
“These diseases typically have a higher incidence in older patients, compounding the issue [15].”
BackgroundNutrition, frailty, and sarcopenia
Cruz-Jentoft, A. J., Kiesswetter, E., Drey, M., & Sieber, C. C. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-016-0709-0 · Cited by 488
Shepherd, J. A., Ng, B. K., Sommer, M. J., & Heymsfield, S. B. (2017) · Bone · doi:10.1016/j.bone.2017.06.010 · Cited by 460
Sandri, M. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.056 · Cited by 451
Kamarajah, S. K., Bundred, J., & Tan, B. H. L. (2019) · Gastric Cancer · doi:10.1007/s10120-018-0882-2 · Cited by 259
Physical Activity and Sarcopenic Obesity: Definition, Assessment, Prevalence and Mechanism
Lee, D.-C., Shook, R. P., Drenowatz, C., & Blair, S. N. (2016) · Future Science OA · doi:10.4155/fsoa-2016-0028 · Cited by 177 · cited 1×
“These patients typically have low muscle mass, indicative of sarcopenia, but also a BMI greater than 30 kg/m(2) (consistent with obesity) [23,24].”
Background
Cited by
Sarcopenia and Cardiovascular Diseases
Damluji, A. A., Alfaraidhy, M., AlHajri, N., Rohant, N. N., Kumar, M., Al Malouf, C., Bahrainy, S., Ji Kwak, M., Batchelor, W. B., Forman, D. E., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064071 · Cited by 645
Metadata
- Authors
- Anjanappa, M., Corden, M., Green, A., Roberts, D., Hoskin, P., McWilliam, A., & Choudhury, A.
- Venue
- Technical Innovations & Patient Support in Radiation Oncology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 16
- Pages
- 50-57
- ISSN
- 2405-6324 (ISSN-L)
- OpenAlex
- W3102262895
- Cited by
- 199
- References
- 24
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.